Search for Companies, Tipsters or Sources…
Companies
Tipsters
Brokers
Sources
Or view the latest share tips
Company Results
Tipster results
Broker results
Sources results
Fund Manager results
Tips from these results
Recent Share tips:
- Buy Victoria (VCP) by Berenberg
- Buy Bank of Ireland Group (CDI) (BIRG) by Deutsche Bank
- Buy Anglo American (AAL) by Deutsche Bank
- Hold Aston Martin Lagonda Global Holdings (AML) by Deutsche Bank
- Buy Intertek Group (ITRK) by Citi
- Neutral British American Tobacco (BATS) by Goldman Sachs
- Neutral Aston Martin Lagonda Global Holdings (AML) by Goldman Sachs
- Equal Weight Whitbread (WTB) by Barclays
- Overweight Travis Perkins (TPK) by Barclays
- Underweight Taylor Wimpey (TW.) by Barclays
- Equal Weight Persimmon (PSN) by Barclays
- Overweight Howden Joinery Group (HWDN) by Barclays
- Overweight Breedon Group (BREE) by Barclays
- Overweight Bellway (BWY) by Barclays
- Equal Weight Vistry Group (VTY) by Barclays
- Neutral Rio Tinto (RIO) by Goldman Sachs
- Overweight Centrica (CNA) by JP Morgan
- Overweight Quilter (QLT) by JP Morgan
- Buy Legal & General Group (LGEN) by Royston Wild in The Motley Fool
- Avoid Thruvision Group (THRU) by Steve Moore in ShareProphets
Shield Therapeutics (STX) Share Price
Health Care Sector
NOTE: This is based on 61 open tips for Shield Therapeutics (STX)
| Latest Bid : 9.50p | Latest Ask : 9.80p |
| High Today : 9.80p | Low Today : 9.50p |
| This Years High : 12.20p | This Years Low : 2.26p |
| Volume : 640,254 | MKT Cap : £76.64M |
| Trading Velocity : Premium Only | Activity Score : Premium Only |
| Consensus Score : Premium Only | Momentum Score : Premium Only |
Shield Therapeutics (STX) Overview
Shield is a de-risked commercial stage, pharmaceutical company focused on addressing iron deficiency in adults with or without anaemia. Our clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make a difference in their everyday lives.Shield Therapeutics (STX) Latest Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Sell | Tom Winnifrith | Premium Only | 2022-06-30 08:40:00 30/06/2022 | 61.25% |
| Sell | Tom Winnifrith | Premium Only | 2022-06-12 17:55:00 12/06/2022 | 82.58% |
| Sell | Tom Winnifrith | Premium Only | 2022-02-18 10:45:00 18/02/2022 | 85.49% |
| Buy | Royston Wild | Premium Only | 2021-08-24 07:40:00 24/08/2021 | -91.65% |
| Buy | Peel Hunt | Premium Only | 2021-06-24 18:00:00 24/06/2021 | -96.56% |
Shield Therapeutics (STX) Active Short Positions
| Fund Manager | Position | Date | ||
|---|---|---|---|---|
| No active short positions | ||||
| Latest Bid : 9.50p | Latest Ask : 9.80p |
| High Today : 9.80p | Low Today : 9.50p |
| This Years High : 12.20p | This Years Low : 2.26p |
| Volume : 640,254 | MKT Cap : £76.64M |
Shield Therapeutics Overview
Shield is a de-risked commercial stage, pharmaceutical company focused on addressing iron deficiency in adults with or without anaemia. Our clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make a difference in their everyday lives.NOTE: This description is in part generated by ChatGPT and not an endorsement by or the opinion of Stockomendation Ltd.
Latest Shield Therapeutics Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Sell | Tom Winnifrith | Premium Only | 2022-06-30 08:40:00 30/06/2022 | 61.25% |
| Sell | Tom Winnifrith | Premium Only | 2022-06-12 17:55:00 12/06/2022 | 82.58% |
| Sell | Tom Winnifrith | Premium Only | 2022-02-18 10:45:00 18/02/2022 | 85.49% |
| Buy | Royston Wild | Premium Only | 2021-08-24 07:40:00 24/08/2021 | -91.65% |
| Buy | Peel Hunt | Premium Only | 2021-06-24 18:00:00 24/06/2021 | -96.56% |